Life Science Investing AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
Life Science Investing AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Life Science Investing AbCellera to Participate at Upcoming Investor Conferences in November and December 2025
Kobo Resources Advances Kossou Toward Resource Definition While Expanding Gold Mineralisation Beyond Known Structures
Nextech3D.ai's KraftyLab Accelerates Global Scale with Launch of In-Person Experiences and AI-Driven Platform Automation
